Negative in Ames, in vitro chromosomal aberration and in vivo mouse micronucleus assays
“Pitolisant and its metabolites were not mutagenic in the in vitro bacterial reverse mutation assay (Ames), or clastogenic in the in vitro mammalian chromosomal aberration assay. Pitolisant was negative in the in vivo mouse micronucleus assay.”
2-year rat and 6-month tgRasH2 mouse: no drug-related neoplasms
“A two-year carcinogenicity study of pitolisant was conducted in rats and a 6-month carcinogenicity study was conducted in tgRasH2 mice. The executive carcinogenicity assessment committee concluded that these studies were adequate and that there were no drug-related neoplasms in either study.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat PPND: stillbirths and pup mortality at maternally toxic doses; teratogenic at 22x MRHD (cleft palate, abnormal limb flexure)
“At the maternally toxic doses, fetal toxicity included stillbirths, postnatal pup mortality (due to lack of milk or failure to nurse) and decreased pup length and weight. Pitolisant was teratogenic at 22 times the MRHD based on mg/m2 , causing major malformations including cleft palate and abnormal limb flexure.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Safety pharmacology
Moderate hERG inhibitor (IC50 1.32 µM); minimal to no QTc effect and no pro-arrhythmic potential in rat, rabbit and dog
“In safety pharmacology studies, pitolisant was a moderate hERG channel inhibitor with an IC50 of 1.32 µM. However, in in vivo studies in rat, rabbit and dog, pitolisant had minimal to no effect on QTc intervals and no pro-arrhythmic potential.”
✓ VerifiedFDA pharmacology/toxicology review, p. 11Source ↗
Genotox: Ames
Negative
“Pitolisant was not genotoxic in an adequate battery of valid genotoxicity studies including bacterial Ames, in vitro mouse lymphoma, and in vivo micronucleus assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 129Source ↗
Genotox: in vitro mammalian
Negative: in vitro mouse lymphoma assay
“Pitolisant was not genotoxic in an adequate battery of valid genotoxicity studies including bacterial Ames, in vitro mouse lymphoma, and in vivo micronucleus assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 129Source ↗
Genotox: in vivo
Negative: in vivo micronucleus
“Pitolisant was not genotoxic in an adequate battery of valid genotoxicity studies including bacterial Ames, in vitro mouse lymphoma, and in vivo micronucleus assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 129Source ↗
Carcinogenicity model
2-year rat and 6-month tgRasH2 mouse; adequate, no drug-related neoplasms
“A two-year carcinogenicity study of pitolisant was conducted in rats and a 6-month carcinogenicity study was conducted in tgRasH2 mice. The executive carcinogenicity assessment committee concluded that these studies were adequate and that there were no drug-related neoplasms in either study.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Carcinogenicity timing
2-year rat and 6-month tgRasH2 mouse studies completed before the marketing application
“A two-year carcinogenicity study of pitolisant was conducted in rats and a 6-month carcinogenicity study was conducted in tgRasH2 mice. The executive carcinogenicity assessment committee concluded that these studies were adequate and that there were no drug-related neoplasms in either study.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
hERG / QT
Moderate hERG inhibitor (IC50 1.32 µM); minimal to no QTc effect and no pro-arrhythmia in rat, rabbit and dog
“In safety pharmacology studies, pitolisant was a moderate hERG channel inhibitor with an IC50 of 1.32 µM. However, in in vivo studies in rat, rabbit and dog, pitolisant had minimal to no effect on QTc intervals and no pro-arrhythmic potential.”
✓ VerifiedFDA pharmacology/toxicology review, p. 11Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative